What is the minimal activity concentation of 18F-FDG so that the initial test goes through. In the manual it says 12.5 MBq/mL, but it doesn't really work. It seems that you should go as high as 37 MBq/mL. What is the reason for discrepancy between the stated minimal concentration and the actual one?
This FDG infusion system can deliver tremendous benefits to a pt dept. more efficient dosing means better schedule flexibility, patient based dosing for lower exposure, and of course, the staffs badge readings will go way down.
WARRENDALE, Pa., May 19, 2011 /PRNewswire/ -- MEDRAD, INC., a business of Bayer HealthCare, has announced the launch of the next generation Intego(TM) PET Infusion System, which features a new design that is 38% smaller, power-driven and includes enhancements to technologist workflow. The new Intego will be on display at the Annual Meeting of the Society of Nuclear Medicine (SNM), June 4-8, in San Antonio, Texas.
The Intego PET Infusion System, originally launched in 2008, remains the only FDA-cleared device for automated, controlled infusion of F18-FDG and F18-NaF, the most common PET diagnostic imaging agents used in oncology. Intego PET Infusion Systems have been sold throughout the world, including the US, Latin America, South America, Europe, Africa, the Middle East, Asia and Australia.
"The new Intego demonstrates our commitment to continued innovation and leadership in molecular imaging. Now, in an even smaller, more mobile design, Intego can significantly reduce radiation exposure and improve patient care. This is just another way we are driving smarter, safer, simpler PET," says Doug Descalzi, executive director, MEDRAD Molecular Imaging.
[b]About MEDRAD, INC.[/b]
MEDRAD, INC. develops, markets and services medical devices used to diagnose and treat disease. Its product offerings include fluid injection systems for radiology and cardiology, endovascular devices for the safe treatment of cardiovascular disease, magnetic resonance-compatible accessories and equipment services. MEDRAD is a two-time recipient of the Malcolm Baldrige National Quality Award, the top honor a U.S. company can receive for quality and business excellence (2003 and 2010). The company's world headquarters is near Pittsburgh, Pennsylvania, in the United States. MEDRAD is a business of Bayer HealthCare. More company information is available at www.medrad.com.
[b]Bayer HealthCare[/b]
The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 16.913 billion (2010), is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare's aim is to discover and manufacture products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 55,700 employees (Dec 31, 2010) and is represented in more than 100 countries. Find more information at www.bayerhealthcare.com.
[b]Forward-looking statements[/b]
This news release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
SOURCE MEDRAD, INC.
Source URL: [url]http://www.qmed.com/news/45520/medrad-launches-second-generation-intego-pet-infusion-system[/url]RE: MedRad - Intego
